MTHFR and MTRR Genetic Polymorphism of Methotrexate Therapy Outcomes in Early Rheumatoid Arthritis

References

• Lin YJ, Anzaghe M, Schülke S. Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis. Cells. 2020;9(4):880.
   PubMed Web of Science ®Google Scholar
• Jekic B, Maksimovic N, Damnjanovic T. Methotrexate pharmacogenetics in the treatment of rheumatoid arthritis. Pharmacogenomics. 2019;20(17):1235–1245. doi:10.2217/pgs-2019-0121
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492–509.
   PubMed Web of Science ®Google Scholar
• Inoue K, Yuasa H. Molecular basis for pharmacokinetics and pharmacodynamics of methotrexate in rheumatoid arthritis therapy. Drug Metab Pharmacokinet. 2014;29(1):12–19.
   PubMed Web of Science ®Google Scholar
• Dervieux T, Greenstein N, Kremer J. Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheum. 2006;54(10):3095–3103.
   PubMed Web of Science ®Google Scholar
• Murto T, Kallak TK, Hoas A, et al. Folic acid supplementation and methylenetetrahydrofolate reductase (MTHFR) gene variations in relation to in vitro fertilization pregnancy outcome. Acta Obstet Gynecol Scand. 2015;94(1):65–71.
   PubMed Web of Science ®Google Scholar
• Li X, Jiang J, Xu M, et al. Individualized supplementation of folic acid according to polymorphisms of methylenetetrahydrofolate reductase (MTHFR), methionine synthase reductase (MTRR) reduced pregnant complications. Gynecol Obstet Invest. 2015;79(2):107–112.
   PubMed Web of Science ®Google Scholar
• Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10(1):111–113.
   PubMed Web of Science ®Google Scholar
• Ashfield-Watt PA, Pullin CH, Whiting JM, et al. Methylenetetrahydrofolate reductase 677C-->T genotype modulates homocysteine responses to a folate-rich diet or a low-dose folic acid supplement: a randomized controlled trial. Am J Clin Nutr. 2002;76(1):180–186.
   PubMed Web of Science ®Google Scholar
• Yamada K, Chen Z, Rozen R, et al. Effects of common polymorphisms on the properties of recombinant human methylenetetrahydrofolate reductase. Proc Natl Acad Sci U S A. 2001;98(26):14853–14858. doi:10.1073/pnas.261469998
   PubMed Web of Science ®Google Scholar
• Froese DS, Huemer M, Suormala T, et al. Mutation update and review of severe methylenetetrahydrofolate reductase deficiency. Hum Mutat. 2016;37(5):427–438. doi:10.1002/humu.22970
   PubMed Web of Science ®Google Scholar
• Hekmatdoost A, Vahid F, Yari Z, et al. Methyltetrahydrofolate vs folic acid supplementation in idiopathic recurrent miscarriage with respect to methylenetetrahydrofolate reductase C677T and A1298C polymorphisms: a randomized controlled trial. PLoS One. 2015;10(12):e0143569. doi:10.1371/journal.pone.0143569
   PubMed Web of Science ®Google Scholar
• Yang J, Luo G, Chen X. Individualized supplement of folic acid based on the gene polymorphisms of MTHER/MTRR reduced the incidence of adverse pregnancy outcomes and newborn defects. Niger J Clin Pract. 2021;24(8):1150–1158. doi:10.4103/njcp.njcp_381_20
   PubMed Web of Science ®Google Scholar
• Du B, Tian H, Tian D, et al. Genetic polymorphisms of key enzymes in folate metabolism affect the efficacy of folate therapy in patients with hyperhomocysteinaemia. Br J Nutr. 2018;119(8):887–895. doi:10.1017/S0007114518000508
   PubMed Web of Science ®Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315–324. doi:10.1002/art.1780310302
   PubMed Web of Science ®Google Scholar
• Aletaha D, Neogi T, Silman AJ, et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–2581. doi:10.1002/art.27584
   PubMed Web of Science ®Google Scholar
• Fransen J, van Riel PL. The disease activity score and the EULAR response criteria. Rheum Dis Clin North Am. 2009;35(4):745–757. doi:10.1016/j.rdc.2009.10.001
   PubMed Web of Science ®Google Scholar
• Ye S, Dhillon S, Ke X, et al. An efficient procedure for genotyping single nucleotide polymorphisms. Nucleic Acids Res. 2001;29(17):E88. doi:10.1093/nar/29.17.e88
   PubMed Web of Science ®Google Scholar
• Kolan SS, Li G, Grimolizzi F, et al. Identification of SNPs associated with methotrexate treatment outcomes in patients with early rheumatoid arthritis. Front Pharmacol. 2022;13:1075603. doi:10.3389/fphar.2022.1075603
   PubMed Web of Science ®Google Scholar
• Wang S, Zuo S, Liu Z, et al. Association of MTHFR and RFC1 gene polymorphisms with methotrexate efficacy and toxicity in Chinese Han patients with rheumatoid arthritis. J Int Med Res. 2020;48(2):300060519879588. doi:10.1177/0300060519879588
   PubMed Web of Science ®Google Scholar
• Lv S, Fan H, Li J, et al. Genetic Polymorphisms of TYMS, MTHFR, ATIC, MTR, and MTRR are related to the outcome of methotrexate therapy for rheumatoid arthritis in a Chinese population. Front Pharmacol. 2018;9:1390. doi:10.3389/fphar.2018.01390
   PubMed Web of Science ®Google Scholar
• Boughrara W, Benzaoui A, Aberkane M, et al. No correlation between MTHFR c.677 C > T, MTHFR c.1298 A > C, and ABCB1 c.3435 C > T polymorphisms and methotrexate therapeutic outcome of rheumatoid arthritis in West Algerian population. Inflammation Res. 2017;66(6):505–513. doi:10.1007/s00011-017-1034-6
   PubMed Web of Science ®Google Scholar
• Berkani LM, Rahal F, Allam I, et al. Association of MTHFR C677T and A1298C gene polymorphisms with methotrexate efficiency and toxicity in Algerian rheumatoid arthritis patients. Heliyon. 2017;3(11):e00467. doi:10.1016/j.heliyon.2017.e00467
   PubMedGoogle Scholar
• Lima A, Bernardes M, Azevedo R, et al. Moving toward personalized medicine in rheumatoid arthritis: sNPs in methotrexate intracellular pathways are associated with methotrexate therapeutic outcome. Pharmacogenomics. 2016;17(15):1649–1674. doi:10.2217/pgs-2016-0067
   PubMed Web of Science ®Google Scholar
• Uribarri M, Ruiz-Larrañaga O, Arteta D, et al. Influence of MTHFR C677T polymorphism on methotrexate monotherapy discontinuation in rheumatoid arthritis patients: results from the GAPAID European project. Clin Exp Rheumatol. 2015;33(5):699–705.
   PubMed Web of Science ®Google Scholar
• Soukup T, Dosedel M, Pavek P, et al. The impact of C677T and A1298C MTHFR polymorphisms on methotrexate therapeutic response in East Bohemian region rheumatoid arthritis patients. Rheumatol Int. 2015;35(7):1149–1161. doi:10.1007/s00296-015-3219-z
   PubMed Web of Science ®Google Scholar
• Iqbal MP, Ali AA, Mehboobali N, et al. Short Communication: lack of association between MTHFR gene polymorphisms and response to methotrexate treatment in Pakistani patients with rheumatoid arthritis. Pak J Pharm Sci. 2015;28(5):1789–1792.
   PubMed Web of Science ®Google Scholar
• Ghodke-Puranik Y, Puranik AS, Shintre P, et al. Folate metabolic pathway single nucleotide polymorphisms: a predictive pharmacogenetic marker of methotrexate response in Indian (Asian) patients with rheumatoid arthritis. Pharmacogenomics. 2015;16(18):2019–2034. doi:10.2217/pgs.15.145
   PubMed Web of Science ®Google Scholar
• Salazar J, Moya P, Altés A, et al. Polymorphisms in genes involved in the mechanism of action of methotrexate: are they associated with outcome in rheumatoid arthritis patients? Pharmacogenomics. 2014;15(8):1079–1090. doi:10.2217/pgs.14.67
   PubMed Web of Science ®Google Scholar
• Lima A, Monteiro J, Bernardes M, et al. Prediction of methotrexate clinical response in Portuguese rheumatoid arthritis patients: implication of MTHFR rs1801133 and ATIC rs4673993 polymorphisms. Biomed Res Int. 2014;2014:368681.
   PubMed Web of Science ®Google Scholar
• Muralidharan N, Gulati R, Misra DP, et al. Nonassociation of homocysteine gene polymorphisms with treatment outcome in South Indian Tamil Rheumatoid Arthritis patients. Clin Exp Med. 2018;18(1):101–107.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME. Methotrexate in rheumatoid arthritis: a quarter century of development. Trans Am Clin Climatol Assoc. 2013;124:16–25.
   PubMedGoogle Scholar
• Lucas CJ, Dimmitt SB, Martin JH. Optimising low-dose methotrexate for rheumatoid arthritis-A review. Br J Clin Pharmacol. 2019;85(10):2228–2234.
   PubMed Web of Science ®Google Scholar
• Maradit-Kremers H, Nicola PJ, Crowson CS, et al. Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis. J Rheumatol. 2006;33(2):248–255.
   PubMed Web of Science ®Google Scholar
• Hoekstra M, van Ede AE, Haagsma CJ, et al. Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis. 2003;62(5):423–426.
   PubMed Web of Science ®Google Scholar
• Jansen G, de Rotte M, de Jonge R. Smoking and methotrexate inefficacy in rheumatoid arthritis: what about underlying molecular mechanisms? J Rheumatol. 2021;48(10):1495–1497.
   PubMed Web of Science ®Google Scholar
• Swierkot J, Slęzak R. Znaczenie badań farmakogenetycznych w efektywności leczenia metotreksatem chorych na reumatoidalne zapalenie stawów (część 2) [The importance of pharmacogenetic tests in evaluation of the effectiveness of methotrexate treatment in rheumatoid arthritis (part 2)]. Postepy Hig Med Dosw. 2011;65:207–215. Polish
   Google Scholar
• Aggarwal P, Naik S, Mishra KP, et al. Correlation between methotrexate efficacy & toxicity with C677T polymorphism of the methylenetetrahydrofolate gene in rheumatoid arthritis patients on folate supplementation. Indian J Med Res. 2006;124(5):521–526.
   PubMed Web of Science ®Google Scholar
• Torres RP, Santos FP, Branco JC. Methotrexate: implications of pharmacogenetics in the treatment of patients with rheumatoid arthritis. ARP Rheumatol. 2022;1(3):225–229.
   PubMedGoogle Scholar
• González-Mercado MG, Rivas F, Gallegos-Arreola MP, et al. MTRR A66G, RFC1 G80A, and MTHFR C677T and A1298C polymorphisms and disease activity in Mexicans with rheumatoid arthritis treated with methotrexate. Genet Test Mol Biomarkers. 2017;21(11):698–704.
   PubMed Web of Science ®Google Scholar
• López-Rodríguez R, Ferreiro-Iglesias A, Lima A, et al. Replication study of polymorphisms associated with response to methotrexate in patients with rheumatoid arthritis. Sci Rep. 2018;8(1):7342.
   PubMedGoogle Scholar
• Chaabane S, Marzouk S, Akrout R, et al. Genetic determinants of methotrexate toxicity in tunisian patients with rheumatoid arthritis: a study of polymorphisms involved in the MTX metabolic pathway. Eur J Drug Metab Pharmacokinet. 2016;41(4):385–393.
   PubMed Web of Science ®Google Scholar
• Kurzawski M, Pawlik A, Safranow K, et al. 677C>T and 1298A>C MTHFR polymorphisms affect methotrexate treatment outcome in rheumatoid arthritis. Pharmacogenomics. 2007;8(11):1551–1559.
   PubMed Web of Science ®Google Scholar
• Kato T, Hamada A, Mori S, et al. Genetic polymorphisms in metabolic and cellular transport pathway of methotrexate impact clinical outcome of methotrexate monotherapy in Japanese patients with rheumatoid arthritis. Drug Metab Pharmacokinet. 2012;27(2):192–199.
   PubMed Web of Science ®Google Scholar
• Bansard C, Lequerré T, Daveau M, et al. Can rheumatoid arthritis responsiveness to methotrexate and biologics be predicted? Rheumatology. 2009;48(9):1021–1028.
   PubMed Web of Science ®Google Scholar
• Siddiqui A, Totonchian A, Jabar Ali JB, et al. Risk factors associated with non-respondence to methotrexate in rheumatoid arthritis patients. Cureus. 2021;13(9):e18112.
   PubMed Web of Science ®Google Scholar